Rare Is The Definition Of Leadership: The Lasting Legacy Of Henri Termeer
Executive Summary
In a recent interview, ProQR’s founder Daniel de Boer cited the enormous impact that fellow Dutch businessman Henri Termer played in getting his fledging biotech start-up off the ground – especially given the circumstances. Some 10 years ago, the then twenty-something budding biotech entrepreneur crossed the Atlantic on a chance that Termeer would answer what amounted to an unscheduled desk-knock at the rare disease pioneer’s office at Genzyme HQ in Cambridge, MA. He did – and the rest is history.
You may also be interested in...
Academia Meets The Market – Part Two
New drug development is an increasingly communal enterprise. In Vivo examines how one major US academic institution – the University of California at Los Angeles (UCLA) – is expanding its range of research contacts to open new areas of therapy and shorten the transition from bench to the bedside.
Academia Meets The Market – Part One
New drug development is an increasingly communal enterprise. In Vivo examines how one major US academic institution – the University of California at Los Angeles (UCLA) – is expanding its range of research contacts to open new areas of therapy and shorten the transition from bench to the bedside. Its commercial impact is considerable: over the past two decades, private-sector VC’s have invested more than $2bn in UCLA-backed innovations, with 26 start-ups launched through the university in 2019 alone. Amir Naiberg, UCLA’s point man on technology transfer, explains the factors that have made the university a successful advocate for partnerships that produce results for patients.
Seeing The Strength In Synergy
In this installment of VC Playbook, profiling venture capital strategies in biopharma and medtech, In Vivo talks to Sofinnova Partners' Graziano Seghezzi about market access trends, Italy’s growing biotech offering and the perils of “health nationalism” to business partnering in the aftermath of COVID-19.
Need a specific report? 1000+ reports available
Buy Reports